CD274 and breast carcinoma: Notably, studies revealed that TNBC has an enrichment of PD-L1 compared to other breast cancer subtypes [231,232,233], which implied that ICIs could be introduced as immunotherapy that antagonizes the immunosuppressive aspect of TNBC, in turn reviving the antitumor effects of T cells [197,234].